Immune Signatures Outperform TILs for HER2-Positive Breast Cancer Prognoses
Immune-related gene expression signatures tracked more closely with treatment response and outcomes than tumor-infiltrating lymphocytes in early-stage HER2-positive breast cancer.
Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients
After documenting excess TMB estimates in non-European cancer patients assessed by tumor-only sequencing, researchers came up with a calibration strategy to address the issue.
Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways
Exome sequences for hundreds of cancer patients led researchers to four recurrently mutated genes and several pathways with ties to immunotherapy response.
Analysis of Tumor Mutation, Treatment Data Across Cancers Points to Predictive Biomarkers
With electronic health record and tumor panel sequence data from tens of thousands of cancer cases, researchers tallied relationships between gene alterations and patient outcomes.